The Med­i­cines Com­pa­ny touts fresh ev­i­dence that their PC­SK9si can durably bat down LDL

The ex­ec­u­tive crew at The Med­i­cines Com­pa­ny say that they re­main on track with an ear­ly-stage PC­SK9 that re­li­ably knocked down lev­els of bad cho­les­terol, clear­ing one more hur­dle in a long jour­ney aimed at de­liv­er­ing a new ther­a­py that can beat out the pi­o­neers in the field with a drug that will on­ly need to be ad­min­is­tered two, three or four times a year.

There’s noth­ing new about PC­SK9 drugs, de­signed to slash LDL. Am­gen and the Re­gen­eron/Sanofi team de­liv­ered back-to-back ther­a­pies that do the same thing. But The Med­i­cines Com­pa­ny be­lieves it can roll up the mar­ket with a new and bet­ter ap­proach in-li­censed from Al­ny­lam that will be much eas­i­er to re­main com­pli­ant on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.